Radiotherapy for local control of osteosarcoma
- PMID: 15667972
- DOI: 10.1016/j.ijrobp.2004.05.051
Radiotherapy for local control of osteosarcoma
Abstract
Purpose: Local control of osteosarcoma in patients for whom a resection with satisfactory margins is not achieved can be difficult. This study evaluated the efficacy of radiotherapy (RT) in this setting.
Methods and materials: We identified 41 patients in our sarcoma database with osteosarcomas that either were not resected or were excised with close or positive margins and who underwent RT with external beam photons and/or protons at our institution between 1980 and 2002. Patient charts were reviewed to assess local control, progression-free survival, metastasis-free survival, and overall survival.
Results: The anatomic sites treated were head/face/skull in 17, extremity in 8, spine in 8, pelvis in 7, and trunk in 1. Of the 41 patients, 27 (65.85%) had undergone gross total tumor resection, 9 (21.95%) subtotal resection, and 5 (12.2%) biopsy only. The radiation dose ranged from 10 to 80 Gy (median 66). Twenty-three patients (56.1%) received a portion of their RT with protons. Chemotherapy was given to 35 patients (85.4%). Of the 41 patients, 27 (65.85%) were treated for localized disease at primary presentation, 10 (24.4%) for local recurrence, and 4 (9.8%) for metastatic disease. The overall local control rate at 5 years was 68% +/- 8.3%. The local control rate according to the extent of resection was 78.4% +/- 8.6% for gross total resection 77.8% +/- 13.9% for subtotal resection, and 40% +/- 21.9% for biopsy only (p < 0.01). The overall survival rate according to the extent of resection was 74.45% +/- 9.1% for gross total resection, 74.1% +/- 16.1% for subtotal resection, and 25% +/- 21.65% for biopsy only (p < 0.001). Patients with either gross or subtotal resection had a greater rate of local control, survival, and disease-free survival compared with those who underwent biopsy only at 5 years (77.7% +/- 7.5% vs. 40% +/- 21% [p <0.001], 73.9% +/- 8.1% vs. 25% +/- 21.6% [p <0.001], and 51.9% +/- 9.1% vs. 25% +/- 21.6% [p <0.01], respectively). Overall survival was better in patients treated at primary presentation (78.8% +/- 8.6% compared with 54% +/- 17.3% for recurrence) p <0.05). No definitive dose-response relationship for local control of tumor was seen, although the local control rate was 71% +/- 9% for 32 patients receiving doses > or =55 Gy vs. 53.6% +/- 20.1% for 9 patients receiving <55 Gy (p = 0.11). Of 15 patients with tumors >5.3 cm, 9 received doses > or =55 Gy and the local control rate was 80% +/- 17.9%, and 6 received doses <55 Gy with a local control rate of only 50% +/- 25% at 5 years (p = 0.16). Among patients who underwent gross total resection, the local control rate was 77.5% +/- 9.95% in 22 patients with negative margins vs 66.7% +/- 27.2% in 3 patients with positive margins (p = 0.54). Two patients had unknown margin status.
Conclusion: RT can help provide local control of osteosarcoma for patients in whom surgical resection with widely, negative margins is not possible. It appears to be more effective in situations in which microscopic or minimal residual disease is being treated.
Similar articles
-
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414206 Clinical Trial.
-
Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity.Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):202-8. doi: 10.1016/j.ijrobp.2005.01.011. Int J Radiat Oncol Biol Phys. 2005. PMID: 16111590
-
The role of radiotherapy in oseosarcoma.Cancer Treat Res. 2009;152:147-64. doi: 10.1007/978-1-4419-0284-9_7. Cancer Treat Res. 2009. PMID: 20213389 Review.
-
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.Pediatr Blood Cancer. 2007 Aug;49(2):145-8. doi: 10.1002/pbc.20904. Pediatr Blood Cancer. 2007. PMID: 16732580
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
Cited by
-
Diaphyseal Tibial Osteosarcoma With Myiasis.Cureus. 2022 Dec 20;14(12):e32718. doi: 10.7759/cureus.32718. eCollection 2022 Dec. Cureus. 2022. PMID: 36686136 Free PMC article.
-
Autophagy and its role in osteosarcoma.Cancer Med. 2023 Mar;12(5):5676-5687. doi: 10.1002/cam4.5407. Epub 2023 Feb 15. Cancer Med. 2023. PMID: 36789748 Free PMC article. Review.
-
Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma.J Neurooncol. 2018 May;137(3):567-573. doi: 10.1007/s11060-018-2746-3. Epub 2018 Jan 11. J Neurooncol. 2018. PMID: 29327171
-
Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313. doi: 10.1016/j.bbrc.2017.03.033. Epub 2017 Mar 12. Biochem Biophys Res Commun. 2017. PMID: 28300555 Free PMC article.
-
Update on Osteosarcoma.Curr Oncol Rep. 2021 Apr 21;23(6):71. doi: 10.1007/s11912-021-01053-7. Curr Oncol Rep. 2021. PMID: 33880674 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical